Decitabine

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5817 publications

Tetrahydrouridine pretreatment increases tissue exposure of 14C-decitabine in mice.

Tetrahydrouridine pretreatment increases tissue exposure of 14C-decitabine in mice.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 18, 2026

Tetrahydrouridine pre-treatment increases tissue exposure of 14C-decitabine in mice.

Tetrahydrouridine pre-treatment increases tissue exposure of 14C-decitabine in mice.

Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 18, 2026

Arginine metabolism supports de novo pyrimidine biosynthesis to block DNA damage and maintain Epstein-Barr virus latency.

Arginine metabolism supports de novo pyrimidine biosynthesis to block DNA damage and maintain Epstein-Barr virus latency.

Journal: mBio
Published: June 15, 2026

Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors.

Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 15, 2026

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Strand-specific quantification of L1 ORF0 and related transcripts by multiplex reverse transcription with tagged primers.

Strand-specific quantification of L1 ORF0 and related transcripts by multiplex reverse transcription with tagged primers.

Journal: BioTechniques
Published: June 08, 2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: June 03, 2026

xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles.

xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles.

Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

Journal: Science advances
Published: May 08, 2026

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026

Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia

Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: April 16, 2026

DNA methylation inhibitor decitabine ameliorates spondyloarthritis by suppressing Th17 responses and epigenetically upregulating VIPR1 in SKG mice.

DNA methylation inhibitor decitabine ameliorates spondyloarthritis by suppressing Th17 responses and epigenetically upregulating VIPR1 in SKG mice.

Journal: Arthritis research & therapy
Published: April 15, 2026
Showing 1-12 of 5,817

Last Updated: 06/30/2026